Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, Germany, Hongkong, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.13
NAS:AMGN's Cash-to-Debt is ranked lower than
79% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:AMGN: 1.13 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AMGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 1.02 Max: N/A
Current: 1.13
Equity-to-Asset 0.39
NAS:AMGN's Equity-to-Asset is ranked lower than
78% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:AMGN: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AMGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.64 Max: 0.85
Current: 0.39
0.33
0.85
Interest Coverage 16.15
NAS:AMGN's Interest Coverage is ranked lower than
83% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:AMGN: 16.15 )
Ranked among companies with meaningful Interest Coverage only.
NAS:AMGN' s Interest Coverage Range Over the Past 10 Years
Min: 5.3  Med: 9.32 Max: 15.52
Current: 16.15
5.3
15.52
Piotroski F-Score: 7
Altman Z-Score: 2.90
Beneish M-Score: -2.63
WACC vs ROIC
10.44%
30.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 43.54
NAS:AMGN's Operating Margin % is ranked higher than
96% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:AMGN: 43.54 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AMGN' s Operating Margin % Range Over the Past 10 Years
Min: 26.94  Med: 33.53 Max: 42.6
Current: 43.54
26.94
42.6
Net Margin % 34.43
NAS:AMGN's Net Margin % is ranked higher than
94% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. NAS:AMGN: 34.43 )
Ranked among companies with meaningful Net Margin % only.
NAS:AMGN' s Net Margin % Range Over the Past 10 Years
Min: 21.43  Med: 27.11 Max: 33.59
Current: 34.43
21.43
33.59
ROE % 26.29
NAS:AMGN's ROE % is ranked higher than
96% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:AMGN: 26.29 )
Ranked among companies with meaningful ROE % only.
NAS:AMGN' s ROE % Range Over the Past 10 Years
Min: 17.14  Med: 21.47 Max: 26.65
Current: 26.29
17.14
26.65
ROA % 10.27
NAS:AMGN's ROA % is ranked higher than
92% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. NAS:AMGN: 10.27 )
Ranked among companies with meaningful ROA % only.
NAS:AMGN' s ROA % Range Over the Past 10 Years
Min: 7.63  Med: 9.57 Max: 12.11
Current: 10.27
7.63
12.11
ROC (Joel Greenblatt) % 152.43
NAS:AMGN's ROC (Joel Greenblatt) % is ranked higher than
95% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. NAS:AMGN: 152.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AMGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 61.87  Med: 82.2 Max: 167.3
Current: 152.43
61.87
167.3
3-Year Revenue Growth Rate 7.70
NAS:AMGN's 3-Year Revenue Growth Rate is ranked higher than
57% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:AMGN: 7.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AMGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.8  Med: 16.1 Max: 121.7
Current: 7.7
5.8
121.7
3-Year EBITDA Growth Rate 16.80
NAS:AMGN's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. NAS:AMGN: 16.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AMGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 16.8 Max: 702.6
Current: 16.8
-1.6
702.6
3-Year EPS without NRI Growth Rate 15.50
NAS:AMGN's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. NAS:AMGN: 15.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AMGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 2.3  Med: 18.7 Max: 124.6
Current: 15.5
2.3
124.6
GuruFocus has detected 2 Warning Signs with Amgen Inc $NAS:AMGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AMGN's 30-Y Financials

Financials (Next Earnings Date: 2017-07-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NYSE:NVO, NAS:CELG, NAS:GILD, NAS:BIIB, NAS:REGN, OTCPK:SHPGF, OTCPK:CSLLY, NAS:VRTX, OTCPK:ALIOY, NAS:ALXN, NAS:INCY, OTCPK:GIKLY, NAS:BMRN, OTCPK:GMXAY, OTCPK:UCBJY, OTCPK:NVZMY, NAS:JAZZ, NAS:ALKS, NAS:SGEN, NAS:TSRO » details
Traded in other countries:AMGN.Argentina, AMGN.Austria, AMGN34.Brazil, AMGN.Chile, AMG.Germany, 04332.Hongkong, AMG N.Mexico, AMGN.Switzerland, 0R0T.UK,
Headquarter Location:USA
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. The Company's business segment is human therapeutics.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolsters the firm's therapeutic oncology portfolio with Nexavar and Kyprolis.

Guru Investment Theses on Amgen Inc

Third Avenue Fund Comments on Amgen - Sep 14, 2016

Livallova

Investor neglect can be a source of new ideas while also providing an element of downside protection. We found this combination to be compelling in our purchase of Livallova (NASDAQ:LIVN), which is the new name for Sorin and Cyberonics post their late-2015 merger. We think investor neglect was paramount, for Sorin, an Italian company, which merged with Cyberonics, based in Houston, changed its name and reincorporated in London. Indeed, we came across the company on a screen of our potential universe of companies, and had to do some digging into the new name we did not recognize, to realize the potential for these two well-known companies and the significant potential their merger offers.

Livallova is a healthcare company with a $3 billion market capitalization that holds leading positions in cardiac surgical equipment, surgical heart valve replacement, neuromodulation and cardiac rhythm management. In its cardiac surgery division, Livallova holds number one positions in Oxygenators and Heart Lung machines. It also is rapidly gaining share with its new sutureless Perceval heart valve, with a history of successful procedures in Europe and recently approved in the U.S. In Neuromodulation, Livallova holds the number one position in devices for the treatment of drug resistant epilepsy, led by its success with its AspireSR device. Livallova is also rapidly gaining share in cardiac rhythm management with Kora250 and Platinium in Japan and Europe, while retaining options on strategies to re-enter the U.S. market. In all, Livallova holds number one positions in over 60% of its revenues.

Livallova also has a strong self-help profile, with targeted synergies from its merger of $80 million over three years. As of its second quarter earnings call, Livallova indicated it was ahead of the first phase of $19 million expected in 2016. Creditworthiness for the company is easily demonstrated by net debt of roughly $75 million.

The ability to compound earnings and book value growth is not only supported by its new product introductions and merger synergies, but also its compelling research and development pipeline, which Livallova refers to as its New Ventures unit. In this unit, Livallova is pursuing groundbreaking new technologies in percutaneous mitral valve repair and replacement, the adaption of its Neuromodulation technologies for treatment of central and obstructive sleep apnea and also the potential to treat heart failure through vagus nerve stimulation. Not only is the potential market opportunity for all three of these areas separately in excess of a billion dollars, but through its merger, Livallova has multiple research efforts in each area to evaluate, streamline and prioritize.

Brexit created a window to initiate a position at under $50 per share for the Fund, which represents a compelling 50% upside to our fair value NAV target. Perhaps due to investor neglect on the name, Livallova trades at a substantial discount to its U.S. peers. We think this discount and its relatively smaller market capitalization also provide downside protection, for the company would likely be attractive to a larger entity looking to expand its product franchise.



From Third Avenue Value Fund's third quarter 2016 letter.



Check out Third Avenue Management,Martin Whitman latest stock trades

Third Avenue Fund Comments on Amgen - Sep 14, 2016

Amgen (NASDAQ:AMGN), which was founded in 1980, is one of the world's leading biotechnology companies. Interestingly, the biotech industry has matured over the years and some of the companies generate stable cash flows, not unlike some of the larger pharmaceutical companies. Amgen is one of these. Competitive issues, largely surrounding the biosimilar debate, have put pressure on Amgen's stock. Post-Brexit market volatility provided us an opportunity to acquire shares.

Amgen has a diversified product portfolio across six therapeutic areas: oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its key products are Enbrel for long-term inflammatory diseases such as rheumatoid arthritis; Epogen and Aranesp for anemia; Neupogen and Neulasta for treating neutropenia (a lack of certain white blood cells caused by cancer, bone marrow transplant, or after chemotherapy). Newer drugs include Repatha, which targets high cholesterol for the roughly 20% of the population who are intolerant of statins (the typical first line treatment), and Kyprolis for multiple myeloma, an incurable bone cancer. Its pipeline consists of 31

preclinical and clinical targets, 12 of which are in the later stages. Amgen also has a pipeline of 9 biosimilars, of which 3 are in late stage and for which the worldwide sales of the originator drugs totaled approximately $54 billion in 2015.

The company generated $9 billion in operating cash flow in 2015, up from $5.1 billion in 2011. The company has used its excess cash flow to fund growth as well as return cash to shareholders via both share buybacks and dividends. It expects to return 60% of adjusted net income to shareholders by 2018.

Amgen has longer-term opportunities for margin improvement from synergies and cost controls. The company initiated a large-scale "transformation" program in 2013 to focus on efficient allocation of resources. The plan included an approximately 23% reduction in its facilities footprint and a 20% reduction in headcount by the end of 2015, with a goal of generating $1.5 billion of annual savings and a 15-point increase in adjusted operating margin by 2018. So far, the company's adjusted operating margin has increased from 38% in 2013 to 48% in 2015 and 55% in 1Q16. Management believes it is on a path to achieve 52-54% by 2018. In addition, the company's new next-generation bio-manufacturing facility is on track. The facility is expected to increase bulk production capabilities at a quarter of capital costs, 1/3 of operating costs and 2x speed vs. conventional facilities, resulting in an estimated cost reduction of 60%+ per gram of protein.

Competitive threats confront any company and even more so for biotech and pharma companies as their products face patent expirations. Biosimilar products are newer to the marketplace and the regulatory pathway is still evolving, with questions of interchangeability with the branded drug still progressing. Biologics are scientifically more challenging than small molecule generic development, more costly to develop and require high-quality complex manufacturing. Price discounting to date has been substantially less than small molecule generics, but may vary over the longer-term. As such, we look to acquire shares at a reasonable estimate of the company's base business without giving much credit to the pipeline. We believe this provides downside protection for the competitive threats while providing opportunity for upside given the growing pipeline. We took advantage of volatility during the quarter to acquire shares of Amgen common at around a 25% discount to our estimate of NAV.



From Third Avenue Value Fund's third quarter 2016 letter.



Check out Third Avenue Management,Martin Whitman latest stock trades

Top Ranked Articles about Amgen Inc

Tracking Portfolio Performance With Risk Analysis A deep look at key portfolio statistics measures
The “Five Criteria for Good Companies” model portfolio generated solid returns during the backtesting period from January 2006-2017, outperforming the Standard & Poor’s 500 exchange-traded fund benchmark in nine of the past 12 years. As of June 20, the portfolio generated a cumulative return of 261.72%, yielding an average excess return of about 5.72%. Read more...
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients
FDA to Examine Amgen's ABP 215 Drug is a biosimilar candidate to a medication for the treatment of various forms of tumors
Amgen Inc. (NASDAQ:AMGN) informed the market June 7 through the PR Newswire that the members of the Food and Drug Administration’s Oncologic Drugs Advisory Committee will get together on July 13 to examine Amgen's Biologics License Application (BLA). Read more...
Amgen Presents Erenumab Data At The 59th Annual Scientific Meeting of the American Headache Society
Amgen To Present At The Goldman Sachs 38th Annual Global Healthcare Conference
Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab
Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe
Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017
Amgen Presents New Phase 2 Data On IMLYGIC® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017
Amgen Showcases A Legacy Of Science, Innovation And Collaboration In Cambridge

Ratios

vs
industry
vs
history
PE Ratio 16.40
AMGN's PE Ratio is ranked higher than
78% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.55 vs. AMGN: 16.40 )
Ranked among companies with meaningful PE Ratio only.
AMGN' s PE Ratio Range Over the Past 10 Years
Min: 10.4  Med: 16.13 Max: 30.95
Current: 16.4
10.4
30.95
Forward PE Ratio 13.89
AMGN's Forward PE Ratio is ranked higher than
75% of the 63 Companies
in the Global Biotechnology industry.

( Industry Median: 22.68 vs. AMGN: 13.89 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 16.40
AMGN's PE Ratio without NRI is ranked higher than
79% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.76 vs. AMGN: 16.40 )
Ranked among companies with meaningful PE Ratio without NRI only.
AMGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.4  Med: 16.13 Max: 30.95
Current: 16.4
10.4
30.95
Price-to-Owner-Earnings 12.87
AMGN's Price-to-Owner-Earnings is ranked higher than
78% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 36.51 vs. AMGN: 12.87 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AMGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.72  Med: 13.2 Max: 29.05
Current: 12.87
9.72
29.05
PB Ratio 4.15
AMGN's PB Ratio is ranked lower than
52% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AMGN: 4.15 )
Ranked among companies with meaningful PB Ratio only.
AMGN' s PB Ratio Range Over the Past 10 Years
Min: 1.8  Med: 3.54 Max: 5.02
Current: 4.15
1.8
5.02
PS Ratio 5.65
AMGN's PS Ratio is ranked higher than
68% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. AMGN: 5.65 )
Ranked among companies with meaningful PS Ratio only.
AMGN' s PS Ratio Range Over the Past 10 Years
Min: 3.01  Med: 4.33 Max: 6.64
Current: 5.65
3.01
6.64
Price-to-Free-Cash-Flow 12.97
AMGN's Price-to-Free-Cash-Flow is ranked higher than
75% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 28.96 vs. AMGN: 12.97 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.79  Med: 12.81 Max: 21.73
Current: 12.97
8.79
21.73
Price-to-Operating-Cash-Flow 11.96
AMGN's Price-to-Operating-Cash-Flow is ranked higher than
76% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 25.50 vs. AMGN: 11.96 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.25  Med: 11.54 Max: 17.29
Current: 11.96
7.25
17.29
EV-to-EBIT 12.31
AMGN's EV-to-EBIT is ranked higher than
69% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. AMGN: 12.31 )
Ranked among companies with meaningful EV-to-EBIT only.
AMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 12.9 Max: 22.6
Current: 12.31
7.4
22.6
EV-to-EBITDA 10.17
AMGN's EV-to-EBITDA is ranked higher than
72% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 18.63 vs. AMGN: 10.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 10.5 Max: 18.2
Current: 10.17
6.2
18.2
PEG Ratio 0.81
AMGN's PEG Ratio is ranked higher than
80% of the 103 Companies
in the Global Biotechnology industry.

( Industry Median: 2.15 vs. AMGN: 0.81 )
Ranked among companies with meaningful PEG Ratio only.
AMGN' s PEG Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1 Max: 3.03
Current: 0.81
0.18
3.03
Shiller PE Ratio 27.11
AMGN's Shiller PE Ratio is ranked higher than
76% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.27 vs. AMGN: 27.11 )
Ranked among companies with meaningful Shiller PE Ratio only.
AMGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.36  Med: 26.85 Max: 57.65
Current: 27.11
17.36
57.65
Current Ratio 4.41
AMGN's Current Ratio is ranked higher than
52% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. AMGN: 4.41 )
Ranked among companies with meaningful Current Ratio only.
AMGN' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 3.02 Max: 9.3
Current: 4.41
1.31
9.3
Quick Ratio 4.14
AMGN's Quick Ratio is ranked higher than
52% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AMGN: 4.14 )
Ranked among companies with meaningful Quick Ratio only.
AMGN' s Quick Ratio Range Over the Past 10 Years
Min: 1.17  Med: 2.68 Max: 9.22
Current: 4.14
1.17
9.22
Days Inventory 238.75
AMGN's Days Inventory is ranked lower than
78% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. AMGN: 238.75 )
Ranked among companies with meaningful Days Inventory only.
AMGN' s Days Inventory Range Over the Past 10 Years
Min: 219.41  Med: 300.96 Max: 374.86
Current: 238.75
219.41
374.86
Days Sales Outstanding 51.71
AMGN's Days Sales Outstanding is ranked higher than
61% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. AMGN: 51.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.32  Med: 52.25 Max: 67.84
Current: 51.71
46.32
67.84
Days Payable 79.52
AMGN's Days Payable is ranked higher than
63% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. AMGN: 79.52 )
Ranked among companies with meaningful Days Payable only.
AMGN' s Days Payable Range Over the Past 10 Years
Min: 54.15  Med: 84.59 Max: 117.72
Current: 79.52
54.15
117.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.49
AMGN's Dividend Yield % is ranked higher than
81% of the 211 Companies
in the Global Biotechnology industry.

( Industry Median: 1.24 vs. AMGN: 2.49 )
Ranked among companies with meaningful Dividend Yield % only.
AMGN' s Dividend Yield % Range Over the Past 10 Years
Min: 0.48  Med: 1.67 Max: 2.8
Current: 2.49
0.48
2.8
Dividend Payout Ratio 0.39
AMGN's Dividend Payout Ratio is ranked higher than
50% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.39 vs. AMGN: 0.39 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AMGN' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.32 Max: 0.39
Current: 0.39
0.14
0.39
3-Year Dividend Growth Rate 28.60
AMGN's 3-Year Dividend Growth Rate is ranked higher than
82% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. AMGN: 28.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AMGN' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 63.3
Current: 28.6
0
63.3
Forward Dividend Yield % 2.65
AMGN's Forward Dividend Yield % is ranked higher than
80% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. AMGN: 2.65 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 14.62
AMGN's 5-Year Yield-on-Cost % is ranked higher than
96% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.57 vs. AMGN: 14.62 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AMGN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.84  Med: 9.88 Max: 16.57
Current: 14.62
2.84
16.57
3-Year Average Share Buyback Ratio 0.70
AMGN's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AMGN: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.1  Med: 0.9 Max: 8.7
Current: 0.7
-10.1
8.7

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 21.39
AMGN's Price-to-Tangible-Book is ranked lower than
91% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. AMGN: 21.39 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AMGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.85  Med: 12.03 Max: 150.81
Current: 21.39
3.85
150.81
Price-to-Intrinsic-Value-Projected-FCF 0.98
AMGN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
88% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 3.46 vs. AMGN: 0.98 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.95 Max: 9.49
Current: 0.98
0.59
9.49
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.86
AMGN's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
77% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.49 vs. AMGN: 0.86 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.30
AMGN's Price-to-Median-PS-Value is ranked lower than
69% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. AMGN: 1.30 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.72  Med: 1.44 Max: 5.16
Current: 1.3
0.72
5.16
Price-to-Peter-Lynch-Fair-Value 0.87
AMGN's Price-to-Peter-Lynch-Fair-Value is ranked higher than
84% of the 77 Companies
in the Global Biotechnology industry.

( Industry Median: 1.85 vs. AMGN: 0.87 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AMGN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.21 Max: 3.33
Current: 0.87
0.58
3.33
Price-to-Graham-Number 3.95
AMGN's Price-to-Graham-Number is ranked lower than
67% of the 190 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. AMGN: 3.95 )
Ranked among companies with meaningful Price-to-Graham-Number only.
AMGN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.52  Med: 3.75 Max: 23.03
Current: 3.95
1.52
23.03
Earnings Yield (Greenblatt) % 8.12
AMGN's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. AMGN: 8.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.4  Med: 7.7 Max: 13.6
Current: 8.12
4.4
13.6
Forward Rate of Return (Yacktman) % 24.63
AMGN's Forward Rate of Return (Yacktman) % is ranked higher than
72% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. AMGN: 24.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AMGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3  Med: 20.2 Max: 95.7
Current: 24.63
3
95.7

More Statistics

Revenue (TTM) (Mil) $22,928.00
EPS (TTM) $ 10.55
Beta1.76
Short Percentage of Float1.10%
52-Week Range $133.64 - 184.21
Shares Outstanding (Mil)735.40

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 22,689 22,586 22,444
EPS ($) 12.24 12.49 12.59
EPS without NRI ($) 12.24 12.49 12.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
2.82%
Dividends per Share ($) 4.61 5.15 5.62
» More Articles for AMGN

Headlines

Articles On GuruFocus.com
Annaly Capital Management: Attractive 9.5% Dividend Yield, but Interest Rates Are a Major Risk Jun 25 2017 
Never a Better Time to Pile on Chipotle Jun 25 2017 
Boeing Takes Lead Over Airbus With $30 Billion Worth of Orders on Day 1 of Paris Air Show Jun 25 2017 
Berkshire Hathaway’s Recent Investment: Home Capital Group Jun 25 2017 
Stocks That Fell to 3-Year Lows in the Week of June 23 Jun 24 2017 
Weekly Top Insider Buys Highlight for the Week of June 23 Jun 24 2017 
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 
Delta and Korean Air Create Leading trans-Pacific Joint Venture Jun 23 2017 
Harwood Feffer LLP Announces Investigation of EnerNOC, Inc. Jun 23 2017 

More From Other Websites
Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion Jun 27 2017
Major Biotech Short Interest Surges Jun 27 2017
Novartis gets European OK for biosimilar of Amgen's Enbrel Jun 27 2017
Regeneron: The End of the Outperformance? Jun 26 2017
Amgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) For The Treatment Of... Jun 23 2017
Deutsche Bank's Take On Big Pharma: 3 Buys And A Hold Jun 23 2017
If Esperion Wants to Market the Next Big Cholesterol Drug, It Will Take Strategy Jun 22 2017
Drugmakers May Lose $390B In Sales Over 5 Years Jun 22 2017
Health-Care Stocks Get a Boost From Senate Bill Rollout Jun 22 2017
Today's Research Reports on Stocks to Watch: Amgen and Incyte Jun 22 2017
Futures: These 2 Big Breakouts Highlight New Market Leadership Jun 22 2017
Amgen An Undervalued Industry Leader Jun 21 2017
Drug stocks rally after Trump decides no price controls—yet: NYSE trader Jun 21 2017
Here's where big oil companies feel the pain of lower crude prices: NYSE trader Jun 21 2017
Here are the biotech stocks the traders are buying Jun 21 2017
Amgen Defends Drug Pipeline, Says the Best is Yet to Come Jun 21 2017
Novartis Migraine Drug Accepted, AMD Positive in Phase III Jun 21 2017
Amgen: In Defense of A Pipeline Jun 21 2017
Amgen To Present New Data At 22nd Congress of the European Hematology Association Jun 21 2017
Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt Jun 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}